Advertisement

Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin

      Cardiovascular disease (CVD) is a well-established co-morbidity of psoriasis, although the precise unifying mechanisms remain unknown. The activity of T-cell populations contribute to the expression of inflammatory cytokines and chemokines, endothelial adhesion molecules, and other factors that underlie the psoriatic disease process and also determine balances in lipid metabolism, cell trafficking, and angiogenesis. Therefore, it has been proposed that abnormal T-cell activity may play a role in the pathogenesis of both the psoriatic and atherosclerotic plaques [
      • Armstrong A.W.
      • Voyles S.V.
      • Armstrong E.J.
      • Fuller E.N.
      • Rutledge J.C.
      A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Armstrong A.W.
        • Voyles S.V.
        • Armstrong E.J.
        • Fuller E.N.
        • Rutledge J.C.
        A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis.
        Exp. Dermatol. 2011; 20: 544-549
        • Goldminz A.M.
        • Suárez-Fariñas M.
        • Wang A.C.
        • Dumont N.M.
        • Krueger J.G.
        • Gottlieb A.B.
        CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial.
        JAMA Dermatol. 2015; 151: 837-846
        • Xiao Y.
        • Xu A.
        • Hui X.
        • Zhou P.
        • Li X.
        • Zhong H.
        Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes.
        PLoS One. 2013; 8: e66607
        • Krueger J.G.
        • Fretzin S.
        • Suarez-Farinas M.
        • Haslett P.A.
        • Phipps K.M.
        • Cameron G.S.
        • et al.
        IL-17A is essential for cell activation and inflammatory gene circuits in psoriasis.
        J. Allergy Clin. Immunol. 2012; 130: 145-154.e9
        • Wang C.Q.F.
        • Suarez-Farinas M.
        • Nograles K.E.
        • Mimoso C.A.
        • Shrom D.
        • Dow E.R.
        • et al.
        IL-17 induces inflammation-associated gene products in blood monocytes and treatment with ixekizumab reduces their expression in psoriasis patient blood.
        J. Invest. Dermatol. 2014; https://doi.org/10.1038/jid.2014.268
        • Davidovici B.B.
        • Sattar N.
        • Prinz J.
        • Puig L.
        • Emery P.
        • Barker J.N.
        • et al.
        Psoriasis and systemic inflammatory diseases:potential mechanistic links between skin disease and co-morbid conditions.
        J. Invest. Dermatol. 2010; 130: 1785-1796
        • Rácz E.P.
        • Prens D.
        • Kurek M.
        • Kant D.
        • de Ridder S.
        • et al.
        Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways.
        J. Invest. Dermatol. 2011; 131: 1547-1558
        • Ahlehoff L.
        • Skov G.
        • Gislason R.
        • Gniadecki L.
        • Iversen L.E.
        • et al.
        Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
        J. Eur. Acad. Dermatol. Venereol. 2015; : 1128-1134
      1. Vascular inflammation in psoriasis trial (the VIP trial (VIP). ClinicalTrials.gov Identifier: NCT01553058.

        • Ridker P.M.
        Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).
        J. Thromb. Haemost. 2009; 7: 332-339